# EDGAR Filing Document

**Accession Number:** 0001759138
**File Stem:** 0001193125-25-138737
**Filing Date:** 2025-6
**Character Count:** 77361
**Document Hash:** 21d68a8fe9a605705948d1e1f9ec86f9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-138737.hdr.sgml**: 20250611

**ACCESSION NUMBER**: 0001193125-25-138737

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 55

**CONFORMED PERIOD OF REPORT**: 20250611

**ITEM INFORMATION**: Termination of a Material Definitive Agreement

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250611

**DATE AS OF CHANGE**: 20250611

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cabaletta Bio, Inc.
- **CENTRAL INDEX KEY:** 0001759138
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** AZ
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39103
- **FILM NUMBER:** 251038723

**BUSINESS ADDRESS:**
- **STREET 1:** 2929 ARCH STREET
- **STREET 2:** SUITE 600
- **CITY:** PHILADELPHIA
- **STATE:** PA
- **ZIP:** 19104
- **BUSINESS PHONE:** (267) 759-3100

**MAIL ADDRESS:**
- **STREET 1:** 2929 ARCH STREET
- **STREET 2:** SUITE 600
- **CITY:** PHILADELPHIA
- **STATE:** PA
- **ZIP:** 19104

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of The Securities Exchange Act of 1934

#### June 11, 2025

#### Date of Report (Date of earliest event reported)

## CABALETTA BIO, INC.

#### (Exact name of Registrant as Specified in its Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39103** | **82-1685768** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(I.R.S. Employer**<br> **Identification No.)** |
| **2929 Arch Street, Suite 600,**<br> **Philadelphia, PA** | **2929 Arch Street, Suite 600,**<br> **Philadelphia, PA** | **19104** |
| **(Address of principal executive offices)** | **(Address of principal executive offices)** | **(Zip Code)** |

---

(267) 759-3100

#### (Registrant's telephone number, including area code)

#### Not Applicable

#### (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| **Title of Each Class** | **Name of Each Exchange**<br> **on Which Registered** |
| Common Stock, par value $0.00001 per share CABA | The Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 1.02** | **Termination of a Material Definitive Agreement.**  |

---

As previously disclosed, on March 21, 2024, Cabaletta Bio, Inc. (the "Company") entered into a Sales Agreement (the "Sales Agreement") with TD Securities (USA) LLC ("TD Cowen"), pursuant to which the Company may sell from time to time, at its option, up to an aggregate of $200,000,000 of shares of the its Common Stock (the "ATM Shares"), through TD Cowen as the Company's sales agent (the "ATM Program").

On June 11, 2025, the Company and TD Cowen mutually agreed to terminate the Sales Agreement effective immediately as of June 11, 2025. The Company is not subject to any termination penalties related to the termination of the Sales Agreement. Prior to termination, 2,609,865 of the ATM Shares had been sold for gross proceeds of $7,881,380, and $192,118,620 of the ATM Shares remained available for sale pursuant to the Sales Agreement. As a result of the termination of the Sales Agreement, the Company will not offer or sell any additional shares under the ATM Program.

A copy of the Sales Agreement was filed as Exhibit 1.2 to the Registration Statement on Form S-3 (File No. 333-278126) filed on March 21, 2024. The description of the Sales Agreement contained in this Current Report on Form 8-K does not purport to be complete and is qualified in its entirety by reference to the copy of the Sales Agreement filed as Exhibit 1.2 to the Registration Statement.

---

| | |
|:---|:---|
| **Item 7.01** | **Regulation FD Disclosure**  |

---

On June 11, 2025, Cabaletta Bio, Inc. ("Cabaletta" or the "Company") issued a press release reporting new clinical and translational data from the ongoing RESET-Myositis<sup>™</sup>, RESET-SLE<sup>™</sup> and RESET-SSc<sup>™</sup> trials evaluating rese-cel (resecabtagene autoleucel, formerly known as CABA-201) (the "Press Release"). A copy of the Press Release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

---

| | |
|:---|:---|
| **Item 8.01** | **Other Events.**  |

---

On June 11, 2025, the Company posted to the "Investors & Media" section of the Company's website at *www.cabalettabio.com* an updated corporate presentation (the "Corporate Presentation"). A copy of the Corporate Presentation is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference.

On June 11, 2025, the Company issued the Press Release.

Cabaletta is presenting new clinical and translational data from 18 evaluable patients who were dosed with rese-cel across the RESET-Myositis<sup>™</sup>, RESET-SLE<sup>™</sup> and RESET-SSc<sup>™</sup> trials at the EULAR 2025 Congress in three oral presentations. As of the data cut-off dates of May 6, 2025, for the RESET-Myositis and RESET-SSc trials and June 2, 2025, for the RESET-SLE trial, key clinical and translational insights from these patients include:

• **RESET-Myositis:** 7 out of 8 patients achieved a clinical response off all immunomodulators, while off or actively tapering steroids. Responses were sustained throughout the follow up period in all responding patients. All 4 antisynthetase syndrome (ASyS) and dermatomyositis (DM) patients achieved a clinically meaningful total improvement score (TIS) response, with 3 of these patients having achieved a major TIS response as of the data cut-off date. Clinically meaningful drug-free responses were observed in 3 of 4 refractory patients with immune-mediated necrotizing myopathy (IMNM), which are consistent with published data. These findings continue to reflect the more modest TIS responses in IMNM compared to other myositis subtypes. Regarding safety, 4 of 8 patients experienced grade 1 CRS (fever), and no Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) was observed.

• **RESET-SLE:** 7 out of 7 patients achieved a clinical response off all immunomodulators and glucocorticoids. All non-renal systemic lupus erythematosus (SLE) patients without nephropathy achieved definition of remission in SLE (DORIS) as of the latest follow-up. The first lupus nephritis (LN) patient achieved DORIS and a complete renal response, while follow-up is continuing on the other two LN patients who were treated more recently. In the 8 patients with safety follow-up, 2 of 8 experienced grade 1 CRS (fever) and 1 ICANS event was observed (grade 4, previously reported).

• **RESET-SSc:** Both of the patients reported in the severe skin cohort had meaningful modified Rodnan Skin Score (mRSS) improvements after discontinuing immunomodulatory drugs and steroids, which was sustained out to 6 months in the first patient. The first patient also met the revised Composite Response Index in Systemic Sclerosis (CRISS) criteria starting at 3 months, highlighting the potential of rese-cel to provide a drug-free, clinical response in patients with systemic sclerosis (SSc). One patient experienced transient grade 2 CRS and one ICANS event was observed (grade 3, previously reported), in addition to a related serious adverse event (SAE) of neutropenic fever.

• **Rese-cel Translational Profile:** Peak rese-cel expansion was observed within approximately two weeks. B cells were rapidly and transiently reduced in peripheral blood within the first month and their repopulation was observed beginning approximately two months after infusion, generally expressing a transitional, naïve phenotype. Tissue-resident B cell depletion was confirmed via a lymph node biopsy in the first systemic sclerosis patient.

------

• In 18 patients with follow-up of 4 weeks or more, 94% had either no cytokine release syndrome (CRS) or Grade 1 CRS (transient fever) and 89% had no ICANS (2 patients with ICANS events previously reported).

RESET<sup>™</sup> clinical trial program enrollment continuing to accelerate, with 51 patients now actively enrolled and 24 patients dosed across industry leading US clinical site network as of May 30, 2025.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.**  |

---

(d) Exhibits

---

| | |
|:---|:---|
| 99.1 | [Press Release issued by the registrant on June 11, 2025, furnished herewith.](d78097dex991.htm) |
| 99.2 | [Corporate Presentation, dated June 11, 2025.](d78097dex992.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL Document). |

---

------

#### SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **CABALETTA BIO, INC.** | **CABALETTA BIO, INC.** |
| Date: June 11, 2025 | By: | /s/ Steven Nichtberger |
|  |  | Steven Nichtberger, M.D. |
|  |  | President and Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**![LOGO](g78097g0611021937651.jpg)

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress

*– 7 of 8 myositis patients achieved clinically meaningful TIS responses after discontinuation of all immunomodulators, while off or actively tapering steroids; responses were sustained throughout the follow-up period in all responding patients –* 

*– All SLE patients without nephropathy achieved definition of remission in SLE (DORIS) as of the latest follow-up, and all 7 SLE and LN patients experienced SLEDAI-2K reductions, while off all immunomodulators and steroids –* 

*– Both scleroderma patients demonstrated clinically compelling mRSS improvement after discontinuation of all immunomodulators and steroids –* 

*– In 18 patients with follow-up of 4 weeks or more, 94% had either no CRS or Grade 1 CRS (transient fever) and 89% had no ICANS (2 patients with previously reported ICANS events) –* 

*– Two registrational myositis cohorts with ~15 patients each are on track to initiate enrollment this year; registrational discussions with FDA are scheduled for SLE/LN in 3Q25, and anticipated for scleroderma in 4Q25 and myasthenia gravis in 1H26 –* 

*– RESET*<sup>™</sup> *clinical trial program enrollment continues to accelerate, with 51 patients now actively enrolled and 24 patients dosed across industry leading US clinical site network as of May 30, 2025 –*

**PHILADELPHIA, June 11, 2025** — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced new clinical and translational data from the ongoing RESET-Myositis<sup>™</sup>, RESET-SLE<sup>™</sup> and RESET-SSc<sup>™</sup> trials evaluating rese-cel (resecabtagene autoleucel, formerly known as CABA-201). These data are being presented in three oral presentations at the ongoing European Alliance of Associations for Rheumatology (EULAR) 2025 Congress, which is being held from June 11-14, 2025, in Barcelona, Spain.

"These new clinical and translational findings reinforce our belief that a single, weight-based dose of rese-cel leads to deep B cell depletion and compelling clinical data in patients with myositis, lupus and systemic sclerosis, with nearly all patients off immunomodulators and steroids. Patients are seeking a drug-free, symptom-free life, which is rarely, if ever, achieved with currently approved therapies. We believe the clinical data on rese-cel indicate its potential to achieve this aspiration and ultimately change treatment paradigms for autoimmune diseases," said David J. Chang, M.D., Chief Medical Officer of Cabaletta. "As we continue to execute across the RESET clinical development program with accelerating enrollment across a broad portfolio of indications with over 50 patients actively enrolled at more than 65 active clinical sites, we plan to leverage our recent FDA alignment on a registrational pathway in myositis to engage in near-term interactions with the FDA on registrational program designs for SLE/LN, SSc and MG and move closer to our goal of launching rese-cel as the first targeted curative cell therapy for patients with autoimmune diseases."

------

Cabaletta is presenting new clinical and translational data from 18 evaluable patients who were dosed with rese-cel across the RESET-Myositis, RESET-SLE and RESET-SSc trials at the EULAR 2025 Congress in three oral presentations. As of the data cut-off dates of May 6, 2025, for the RESET-Myositis and RESET-SSc trials and June 2, 2025, for the RESET-SLE trial, key clinical and translational insights from these patients include:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **RESET-Myositis:** 7 out of 8 patients achieved a clinical response off all immunomodulators, while off or
actively tapering steroids. All 4 antisynthetase syndrome (ASyS) and dermatomyositis (DM) patients achieved a clinically meaningful total improvement score (TIS) response, with 3 of these patients having achieved a major TIS response as of the data cut-off date. Clinically meaningful drug-free responses were observed in 3 of 4 refractory patients with immune-mediated necrotizing myopathy (IMNM), which are consistent with published data. These findings continue
to reflect the more modest TIS responses in IMNM compared to other myositis subtypes. Regarding safety, 4 of 8 patients experienced grade 1 CRS (fever), and no ICANS was observed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **RESET-SLE:** 7 out of 7 patients achieved a clinical response off
all immunomodulators and glucocorticoids. All non-renal systemic lupus erythematosus (SLE) patients without nephropathy achieved DORIS as of the latest follow-up. The
first lupus nephritis (LN) patient achieved DORIS and a complete renal response, while follow-up is continuing on the other two LN patients who were treated more recently. In the 8 patients with safety follow-up, 2 of 8 experienced grade 1 CRS (fever) and 1 ICANS event was observed (grade 4, previously reported).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **RESET-SSc:** Both of the patients reported in the severe skin cohort had meaningful modified Rodnan Skin
Score (mRSS) improvements after discontinuing immunomodulatory drugs and steroids, which was sustained out to 6 months in the first patient. The first patient also met the revised Composite Response Index in Systemic Sclerosis (CRISS) criteria
starting at 3 months, highlighting the potential of rese-cel to provide a drug-free, clinical response in patients with systemic sclerosis (SSc). One patient experienced transient grade 2 CRS and one ICANS event was observed (grade 3, previously
reported).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Rese-cel Translational Profile:** Peak rese-cel expansion was observed within approximately two weeks. B
cells were rapidly and transiently reduced in peripheral blood within the first month and their repopulation was observed beginning approximately two months after infusion, generally expressing a transitional, naïve phenotype. Tissue-resident B
cell depletion was confirmed via a lymph node biopsy in the first systemic sclerosis patient.

Additional information can be accessed on the website of the EULAR 2025 Congress. Presentation materials will be made available after they occur on the Posters & Publications section of the Company's website.

------

**About rese-cel (formerly referred to as CABA-201)** 

Rese-cel is a 4-1BB-containing fully human CD19-CAR T cell investigational therapy for patients with autoimmune diseases where B cells contribute to the initiation and/or maintenance of disease. Following a one-time infusion of a weight-based dose, rese-cel is designed to transiently and deeply deplete all CD19-positive cells in both the peripheral circulation and within tissues. Cabaletta believes this approach has the potential to reset the immune system and result in profound clinical responses without chronic therapy requirements in patients. Cabaletta is currently evaluating rese-cel in the RESET<sup>™</sup> (REstoring SElf-Tolerance) clinical development program which includes multiple disease-specific, company-sponsored clinical trials across expanding portfolios of autoimmune diseases in a broad range of therapeutic areas, including rheumatology, neurology and dermatology.

**About Cabaletta Bio** 

Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases. The CABA<sup>™</sup> platform encompasses two complementary strategies which aim to advance the discovery and development of engineered T cell therapies with the potential to become deep and durable, perhaps curative, treatments for a broad range of autoimmune diseases. The lead CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) strategy is prioritizing the development of rese-cel, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy. Rese-cel is currently being evaluated in the RESET<sup>™</sup> (REstoring SElf-Tolerance) clinical development program spanning multiple therapeutic areas, including rheumatology, neurology and dermatology. Cabaletta Bio is planning to evaluate rese-cel in two, independent registrational cohorts within myositis, and anticipates aligning with the FDA on the registrational cohort design for studies in SLE/LN, SSc, and MG. Cabaletta Bio's headquarters and labs are located in Philadelphia, PA. For more information, please visit <u>www.cabalettabio.com</u> and connect with us on LinkedIn.

**Forward-Looking Statements** 

This press release contains "forward-looking statements" of Cabaletta Bio within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including without limitation, express or implied statements regarding: Cabaletta's business plans and objectives as a whole; Cabaletta's ability to realize its vision of launching the first curative targeted cell therapy designed specifically for patients with autoimmune diseases; Cabaletta's ability to successfully complete research and further development and commercialization of its drug candidates in current or future indications, including the timing and results of Cabaletta's clinical trials and its ability to conduct and complete clinical trials; expectation that clinical results will support rese-cel's safety and activity profile; statements regarding the timing of interactions with regulatory authorities, including such authorities' review of safety information from Cabaletta's ongoing clinical trials and potential registrational pathway for rese-cel; Cabaletta's ability to leverage its emerging clinical data and its efficient development strategy; Cabaletta's ability to capitalize on and potential benefits resulting from its research and translational insights; including those related to any similarly-designed constructs or dosing regimens; Cabaletta's expectation regarding the clinical data to be presented at the EULAR congress; Cabaletta's expectations around the potential success and therapeutic benefits of rese-cel; the Company's advancement of separate Phase 1/2 clinical trials of rese-cel in patients with SLE, myositis, SSc and gMG and advancement of the RESET-PV and RESET-MS trials, including updates related to status, safety data, efficiency of clinical trial design and timing of data read-outs or otherwise; Cabaletta's expectations to initiate enrollment in two myositis registrational cohorts in 2025; Cabaletta's belief that the clinical data on rese-cel indicates its potential for patients to achieve a drug-free, symptom-free life and ultimately change treatment paradigms for autoimmune diseases; Cabaletta's plans to

------

leverage its recent FDA alignment on a registrational pathway in myositis to engage in near-term interactions with the FDA on registrational program designs for SLE/LN, SSc and MG, and move closer to its goal of launching rese-cel as the first targeted curative cell therapy for patients with autoimmune diseases; Cabaletta's timing of registrational discussions with FDA for SLE/LN in 3Q25 and anticipated timing of registrational discussions with FDA for scleroderma in 4Q25 and myasthenia gravis in 1H26.

Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to regulatory filings and potential clearance; the risk that signs of biologic activity or persistence may not inform long-term results; Cabaletta's ability to demonstrate sufficient evidence of safety, efficacy and tolerability in its preclinical studies and clinical trials of rese-cel; the risk that the results observed with the similarly-designed construct employed in academic publications, including due to the dosing regimen, are not indicative of the results we seek to achieve with rese-cel; risks that modifications to trial design or approach may not have the intended benefits and that the trial design may need to be further modified; risks related to clinical trial site activation, delays in enrollment generally or enrollment rates that are lower than expected; delays related to assessment of clinical trial results; risks related to unexpected safety or efficacy data observed during clinical studies; risks related to volatile market and economic conditions and public health crises; Cabaletta's ability to retain and recognize the intended incentives conferred by Regenerative Medicine Advanced Therapy, Orphan Drug Designation and Fast Track Designation or other designations for its product candidates, as applicable; risks related to Cabaletta's ability to protect and maintain its intellectual property position; risks related to fostering and maintaining successful relationships with Cabaletta's collaboration and manufacturing partners; uncertainties related to the initiation and conduct of studies and other development requirements for its product candidates; the risk that any one or more of Cabaletta's product candidates will not be successfully developed and/or commercialized; the risk that the initial or interim results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies; the Company's ability to fund its operations and continue as a going concern. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Cabaletta's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in Cabaletta's most recent annual report on Form 10-K as well as discussions of potential risks, uncertainties, and other important factors in Cabaletta's other subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Cabaletta undertakes no duty to update this information unless required by law.

**Contacts:** 

Anup Marda

Chief Financial Officer

<u>investors@cabalettabio.com</u>

## Exhibit 99.2

![Slide 1](g78097ex99_2s1g1.jpg)

Corporate Presentation JUNE 2025 Exhibit 99.2

------

![Slide 2](g78097ex99_2s2g1.jpg)

Disclaimer This presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document distributed at or in connection with the presentation (collectively, the "Presentation") has been prepared by Cabaletta Bio, Inc. ("we," "us," "our," "Cabaletta" or the "Company") and may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, and financial conditions, and include, but are not limited to, express or implied statements regarding our current beliefs, expectations and assumptions regarding: our business, future plans and strategies for our technology; our ability to grow our autoimmune-focused pipeline; the ability to capitalize on and potential benefits resulting from our research and translational insights, including those related to any similarly-designed constructs or dosing regimens; the anticipated market opportunities for rese-cel in patients with autoimmune diseases; the Company's business plans and objectives; our expectations around the potential success and therapeutic and clinical benefits of rese-cel, as well as our ability to successfully complete research and further development and commercialization of our drug candidates in current or future indications, including the timing and results of our clinical trials and our ability to conduct and complete clinical trials; expectation that clinical results will support rese-cel's safety and activity profile; our plan to leverage increasing clinical data and a unique development program for rese-cel; the clinical significance and impact of clinical data read-outs, including the progress, results and clinical data from each of the patients dosed with rese-cel in the Phase 1/2 RESET-Myositis, RESET-SLE and the RESET-SSc trials and our other planned activities with respect to rese-cel; our belief that rese-cel has the potential to provide drug-free, durable meaningful clinical responses, through an immune reset, including the potential for achieving drug-free remission in patients with refractory myositis; the Company's advancement of separate Phase 1/2 clinical trials of rese-cel and advancement of the RESET-PV and RESET-MS trials, including updates related to status, safety data, efficiency of clinical trial design and timing of data read-outs or otherwise; our ability to leverage our experience in autoimmune cell therapy; our ability to enroll the requisite number of patients, dose each dosing cohort in the intended manner and timing thereof, and advance the trial as planned in our Phase 1/2 clinical trials of rese-cel; the timing any planned regulatory filings for our development programs, including IND applications and interactions with regulatory authorities, including such authorities' review of safety information from our ongoing clinical trials and potential registrational pathway for rese-cel; our ability to successfully complete our preclinical and clinical studies for our product candidates, including our ability to progress the trial; Cabaletta's advancement of the whole blood manufacturing program to remove the burden of apheresis; our ability to increase enrollment from our rapidly expanding clinical network in the RESET clinical trial program in the US and Europe; our ability to obtain and maintain regulatory approval of our product candidates, including our expectations regarding the intended incentives conferred by and ability to retain regulatory designations and the anticipated initiation of registrational cohorts and potential BLA submission; our belief regarding alignment with FDA on registrational trial design and timing thereof; our ability to accelerate our pipeline to approval and launch and to develop meaningful therapies for patients, including in collaboration with academic and industry partners and the ability to optimize such collaborations on our development programs; our ability to contract with third-party suppliers and manufacturers; our ability to execute our manufacturing strategy to enable expansion of clinical supply and efficiently scale commercial supply for rese-cel; our potential commercial opportunities, including value and addressable market, for our product candidates. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "would," "should" and "could," and similar expressions or words, identify forward-looking statements. Various risks, uncertainties and assumptions could cause actual results to differ materially from those anticipated or implied in our forward-looking statements. Such risks and uncertainties include, but are not limited to, risks related to the success, cost, and timing of our development activities and clinical trials, risks related to our ability to demonstrate sufficient evidence of safety, efficacy and tolerability in our clinical trials, the risk that the results observed with the similarly-designed construct, including, but not limited to, dosing regimen, are not indicative of the results we seek to achieve with rese-cel, the risk that signs of biologic activity or persistence may not inform long-term results, risks related to clinical trial site activation or enrollment rates that are lower than expected, risks that modifications to trial design or approach may not have the intended benefits and that the trial design may need to be further modified; our ability to protect and maintain our intellectual property position, risks related to our relationships with third parties, uncertainties related to regulatory agencies' evaluation of regulatory filings and other information related to our product candidates, our ability to retain and recognize the intended incentives conferred by any regulatory designations, risks related to regulatory filings and potential clearance, the risk that any one or more of our product candidates will not be successfully developed and commercialized, the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies, risks related to volatile market and economic conditions and our ability to fund operations and continue as a going concern. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ materially from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our most recent annual report on Form 10-K and quarterly report on From 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in our other filings with the Securities and Exchange Commission. Certain information contained in this Presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this Presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. The Company is the owner of various trademarks, trade names and service marks. Certain other trademarks, trade names and service marks appearing in this Presentation are the property of third parties. Solely for convenience, the trademarks and trade names in this Presentation are referred to without the® and TM symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.

------

![Slide 3](g78097ex99_2s3g1.jpg)

Develop and launch the first curative targeted cellular therapies for patients with autoimmune diseases

------

![Slide 4](g78097ex99_2s4g1.jpg)

Rapidly accelerating enrollment across a broad portfolio of indications at 67 active clinical sites2 Rese-cel1: 2027 BLA submission planned following recent FDA alignment SLE – systemic lupus erythematosus; LN – lupus nephritis; SSc – systemic sclerosis; BLA – biologics license application. resecabtagene autoleucel; CABA-201 As of May 30, 2025. As of data cut-off of May 6, 2025 (as of June 2, 2025 for RESET-SLE study). Initial BLA submission planned in myositis (~80K US pts), followed by rapid expansion to SLE/LN & SSc Aligned with FDA on open-label, single arm evaluation of two registrational cohorts in RESET-Myositis trial N ~15 in each subtype specific cohort; enrollment on track to initiate in 2H25 Leveraging myositis alignment to gain registrational design agreement with FDA for SLE/LN (3Q25) & SSc (4Q25) Emerging clinical data & innovative development strategy facilitate accelerated timeline to approval & launch Study designs, endpoints and clinical data support small registrational cohorts Disease-specific efficacy and safety data, supplemented by safety data from entire RESET clinical program Registrational cohorts use the same weight-based dose, consistent entry criteria, same sites as Phase 1/2 cohorts Compelling clinical efficacy, favorable safety and deep B cell depletion observed in myositis, SLE/LN and SSc Clinically meaningful responses with most patients off all immunomodulatory medications and steroids3 Deep transient systemic B cell depletion in blood and tissues; confirmed by lymph node biopsy in an SSc patient Rese-cel clinical data on 1st 18 patients presented in 3 oral sessions at the EULAR 2025 congress Patients are seeking a drug-free, symptom-free life, which is rarely achieved with current therapies

------

![Slide 5](g78097ex99_2s5g1.jpg)

Disease-specific cohorts in RESET clinical program are designed to evolve directly into registrational studies Innovative clinical strategy to support accelerated regulatory path Program1 Trial Preclinical Phase 1/2 Registrational Rese-cel (CABA-201) 4-1BB CD19-CAR T RESET-Myositis™ CARTA Chimeric Antigen Receptor T cells for Autoimmunity RESET-SLE™ RESET-SSc™ RESET-MG™ RESET-MS™ RESET-PV™ Dermatomyositis Antisynthetase syndrome Immune-mediated necrotizing myopathy Lupus Nephritis Non-Renal SLE Skin + Organ Cohort AChR-Ab neg. gMG AChR-Ab pos. gMG Skin Cohort Rheumatology2 Neurology Dermatology FTD Mucocutaneous & mucosal pemphigus vulgaris Contains cohort(s) without preconditioning Juvenile Myositis Pediatric Indication RESET™ – REstoring SElf-Tolerance; Ab – Antibody; AChR – Acetylcholine receptor; gMG – Generalized myasthenia gravis; MS – Multiple sclerosis; SLE – Systemic lupus erythematosus Additional pipeline candidate includes MuSK-CAART for MuSK-Ab positive MG, currently being evaluated in a Phase 1 trial. Myositis patients can also be treated by neurologists or dermatologists; lupus nephritis patients can also be treated by nephrologists. FDA Fast Track Designation received in dermatomyositis, SLE and lupus nephritis, systemic sclerosis, and multiple sclerosis. FDA Regenerative Medicine Advanced Therapy (RMAT) received in myositis. Progressive MS Relapsing MS RMAT

------

![Slide 6](g78097ex99_2s6g1.jpg)

Rapidly completing enrollment in Phase 1/2 RESET™ trial cohorts Data per clinicaltrials.gov as of May 30, 2025, as compared to companies with actively recruiting U.S. clinical sites for autoimmune cell therapy trials under company-sponsored INDs. As of May 30, 2025. SLE sites Myositis sites MG sites SSc sites PV sites +4 Europe clinical sites Industry-leading US clinical site footprint with 67 clinical sites recruiting in the US & Europe1 51 patients actively enrolled & 24 dosed2 Multiple Phase 1/2 cohorts fully enrolled2

------

![Slide 7](g78097ex99_2s7g1.jpg)

7 FDA alignment recently achieved in Type C meeting for rese-cel; two open-label, single-arm cohorts to evaluate outcomes FDA aligned on key design elements of myositis registrational cohorts Registrational Cohorts2 ASyS DM & ASyS (n ~15) Initial Phase 1/2 Cohorts1 DM IMNM (n ~6) IMNM (n ~15) (combined n ~6) TIS, total improvement score. Pediatric submission based on data available at the time of adult submission from ongoing Ph 1/2 study (no new study) to support pediatric label claim Size of myositis registrational cohorts based on key statistical parameters aligned upon with the FDA and background remission rate in myositis. As of May 30, 2025. Subsequent indications anticipated to be submitted as an sBLA (Supplemental Biologics License Application). 2027 BLA submission planned in myositis; initiation of registrational cohorts anticipated in 2025 Expansion of current RESET-Myositis trial to include two registrational cohorts Evaluating a primary endpoint based on the TIS, a validated endpoint in myositis, within 26 weeks of rese-cel infusion Confirmed current dose of 1 million cells/kg Safety database ~100 autoimmune patients at ≥1-month of follow-up (with at least 35 myositis patients) Over 40% of the safety database already enrolled across the RESET clinical development program3 BLA for either registrational cohort may be submitted independently4 P P P P P

------

![Slide 8](g78097ex99_2s8g1.jpg)

Planning to leverage recent myositis FDA alignment and execution across the portfolio of indications Anticipated Rese-cel Milestones with 2027 BLA Submission Planned 1H25 2H25 1H26 2H26 Align with FDA on registrational cohort designs Present complete Phase 1/2 data Initiate enrollment in registrational cohorts No preconditioning (RESET-PV) CMC commercial supply readiness & innovation Dose escalation data2 Initial dose data Commercial process implemented Lupus SSc Myositis MG Lupus SSc MG Myositis Myositis FDA alignment: Safety comparability EULAR interim data Myositis, Lupus & SSc Initial clinical data w/ Cellares process3 CONFIDENTIAL Subject to data and FDA alignment on proposed registrational cohort design.. Subject to review of initial dose cohort data. Pending final agreement with Cellares to advance technology. Additional indication(s): Lupus, SSc & MG1

------

![Slide 9](g78097ex99_2s9g1.jpg)

Chimeric Antigen Receptor T Cells for Autoimmunity (rese-cel)

------

![Slide 10](g78097ex99_2s10g1.jpg)

~150 autoimmune patients have been dosed with a range of autologous CAR T constructs (industry & academia)1 Autologous CAR T is potentially transformational for autoimmunity IIM – idiopathic inflammatory myopathy; MG – Myasthenia gravis; MS – Multiple sclerosis; SPS – Stiff person syndrome; SSc – Systemic sclerosis. Note: 'Other' indications includes CIDP, IgG4-related disease, ANCA-associated vasculitis, NMOSD, Lambert Eaton myasthenic syndrome, autoimmune encephalitis. Data as of November 2024 (ACR Convergence 2024) based on Cabaletta Bio literature review across industry and academia. Müller, Fabian, et al. "BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells." Nat Med (2025). Compelling immunomodulator-free clinical responses observed across many autoimmune diseases, durable for up to 4 years Clinical recurrences observed in <5% of ~150 treated patients IIM patient relapsed post CD19-CAR T after ~9 months of drug-free remission2 No evidence of CD19 escape or failure Patient treated with BCMA-CAR T & now in remission2 ~150 Patients Treated (by Disease) Type of CAR T Construct Efficacy Observations1 Safety Observations1 Among ~150 autoimmune patients dosed with cell therapy, frequency and severity of CRS/ICANS events were considerably lower than those observed in cancer patients Vaccine titers stable with CD19-CAR T mono-targeting therapy insufficient data with CD19xBCMA-CAR T 31% 60% 8%

------

![Slide 11](g78097ex99_2s11g1.jpg)

Rese-cel binder with similar in vitro & in vivo activity to construct used in academic studies in autoimmunity1,3 Rese-cel: CD19-CAR T specifically designed for autoimmunity Peng, Binghao J, et al. "Preclinical specificity and activity of CABA-201, a fully human 4-1BB containing CD19 CAR T therapy for treatment-resistant autoimmune disease." Poster presented at: American Society Gene and Cell Therapy 26th Annual Meeting; 2023 May 19; Los Angeles, CA. Dai, Zhenyu, et al. "Development and functional characterization of novel fully human anti-CD19 chimeric antigen receptors for T-cell therapy." Journal of Cellular Physiology 236.8 (2021): 5832-5847. Müller, Fabian, et al. "CD19 CAR T-Cell Therapy in Autoimmune Disease—A Case Series with Follow-up." New England Journal of Medicine 390.8 (2024): 687-700. Maschan, Michael, et al. "Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients." Nature Communications 12, 7200 (2021) Transmembrane domain in rese-cel is CD8α vs. TNFRSF19 (Troy) utilized in the academic construct. The two transmembrane domains have not been shown to have a significant difference in function or IFN-γ production in preclinical studies. The CD8α transmembrane domain is employed in tisagenlecleucel. Volkov, Jenell, et al. "Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-Myositis phase I/II trial." Molecular Therapy 32.11 (2024): 3821-3828. Abstract 1733: Safety and Efficacy of CABA-201, a Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Patients with Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus from the RESET-MyositisTM and RESET-SLETM Clinical Trials. ACR 2024. Rese-cel product design & clinical / translational data 4-1BB costimulatory domain with fully human binder Binder with similar affinity & biologic activity to academic FMC63 binder while binding to the same epitopes1,2 Same weight-based dose as in academic studies Potential to provide immune reset based on initial clinical and translational data5 Initial patients treated with rese-cel have shown compelling clinical responses with safety data that supports autoimmune development6 Fully human anti-CD19 binder 4-1BB costimulatory domain CD3-z signaling domain Rese-cel4

------

![Slide 12](g78097ex99_2s12g1.jpg)

Broad portfolio with six RESET trials designed to address high unmet need and realize the potential of rese-cel RESET™ program advancing trials in a broad portfolio of diseases SLE – Systemic lupus erythematosus; DM – Dermatomyositis; SSc – Systemic sclerosis; gMG – Generalized myasthenia gravis; MS – multiple sclerosis; ESRD – End-stage renal disease; PV – pemphigus vulgaris SSc gMG PV ~90k ~55k ~15k Middle age onset common Progressive skin & organ fibrosis with lung, cardiac, renal damage Average survival of 12y Bimodal age of onset Profound weakness that can be disabling Risk for myasthenic crises, with respiratory failure Rheum Neuro Derm No Flu/Cy Pure autoantibody & B-cell mediated autoimmune disease Characterized by painful blisters & erosions SLE/LN ~320k Affects young women & people of color ~30-40% with lupus nephritis, which carries ~25% risk of death or ESRD within 10y > > > Myositis ~80k Typical onset middle age Only FDA-approved therapy is IVIg in DM Three-fold increased mortality due to lung & cardiac involvement > MS ~750k Chronic inflammation, axon loss, cognitive impairment, and irreversible neurologic damage > ~85k ~150k ~60k ~100k ~550k ~20k U.S. Prevalence EU Prevalence

------

![Slide 13](g78097ex99_2s13g1.jpg)

Myositis: Unmet Need

------

![Slide 14](g78097ex99_2s14g1.jpg)

High rates of disability; increased mortality risk Myositis: A disease of significant unmet need High disease burden: disability & mortality Typical patient is a middle-aged female who experiences muscle weakness, fatigue, pain, shortness of breath and difficulty swallowing Moderate to severe disability (40% to 65%)1 Assisted walking devices (18% to 38%)1 The risk of mortality is ~3 times higher than the general population, primarily due to cancer and lung & cardiac complications2 ~20% mortality < 5 years with standard immunosuppressive treatment3 "I find it very difficult to get up from a regular chair, I need boosters or assistance from somebody else. Walking, my gait has really suffered. My stability walking has suffered as well, and I can't lift anything more than five or eight pounds. So doing stuff is difficult. Bending down is very difficult. I can't get up from the floor if I fall." "John" 61-year-old male with ASyS4 ~10 yrs since diagnosis "Susan" 66-year-old female with IMNM4 ~13 yrs since diagnosis "I had really acute onset muscle weakness and muscle wasting. I could just see where there were certain parts of my body where basically my body was disappearing, and I was losing the ability to do things that I would normally do with no problem… it became very difficult to go up the stairs. I would have to, for instance, grab the cloth on my pants to lift my leg up to get it up the next step." "It just affected every aspect of my life. Just work, family, social life, own wellbeing. It just pours into everything else with that." "Erica" 44-year-old female with DM4 ~2.5 yrs since diagnosis Opinc AH, Brzezinska OE, Makowska JS. Disability in idiopathic inflammatory myopathies: questionnaire-based study. Rheumatol Int. 2019;39(7):1213-1220. Marie I. Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Rep. 2012;14(3):275-285. Schiopu E, Phillips K, MacDonald PM, Crofford LJ, Somers EC. Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. Arthritis Res Ther. 2012;14(1):R22. Primary market research conducted via third-party, blinded interviews with myositis patients, conducted in 2024.

------

![Slide 15](g78097ex99_2s15g1.jpg)

IVIg is the only approved therapy (only for patients with the adult dermatomyositis subtype) Myositis: Limited treatment options for ~80k U.S. patients Lundberg, Ingrid E., et al. "Idiopathic inflammatory myopathies." Nature Reviews Disease Primers 7.1 (2021): 86. Analysis from quantitative survey of U.S. myositis-treating physicians, conducted 2Q25. N = ~240. Autoimmune disease with B cells component Limited treatment options1 Idiopathic inflammatory myopathies (IIMs, or myositis) are a group of autoimmune diseases characterized by inflammation and muscle weakness Common therapies: steroids plus an immunomodulator (i.e. methotrexate, azathioprine, mycophenolate, rituximab) IVIg (intravenous immunoglobulin), the only FDA-approved therapy, is approved in adult dermatomyositis Therapies can carry potential long-term side effects such as serious infections and organ damage Despite existing therapies, disease is often refractory Myositis patients with moderate to severe, refractory disease potentially eligible for rese-cel (per analysis of quantitative research with ~240 myositis-treating physicians) Eligible U.S. myositis patients2 ~16k to 20k U.S. myositis patients eligible for rese-cel ~80k myositis patients

------

![Slide 16](g78097ex99_2s16g1.jpg)

Rese-cel Clinical & Translational Data

------

![Slide 17](g78097ex99_2s17g1.jpg)

Individual trials in myositis, SLE, and SSc share common elements of preconditioning, dose, and study design RESETTM clinical trials have consistent design principles1 †Follow up period encompasses 15 years in total, aligned to regulatory guidance for CAR T cell therapies. AE, adverse event; CABA, Cabaletta Approach to B cell Ablation; FLU, fludarabine; CY, cyclophosphamide; PBMC, peripheral blood mononuclear cell; PD, pharmacodynamics; PK, pharmacokinetics; RESET, REstoring SElf-Tolerance; SLE, systemic lupus erythematosus; SSc, systemic sclerosis. Cabaletta Bio: Data on file; 1. Peng BJ, et al. Mol Ther Methods Clin Dev. 2024;32(2):101267. Leukapheresis and CABA-201 production Preconditioning Single infusion of CABA-201 Weight-based dosing 1×106 cells/kg Day 1 Primary endpoint: Incidence and severity of AEs T cells isolated from patient's own PBMCs (autologous CAR T) Day 29 Study follow-up through Year 3† Screening Additional Endpoints Clinical efficacy measuring: Drug-free responses Validated study-specific endpoints PK/PD analysis: CABA-201 expansion B cell depletion B cell repopulation Adverse events & safety Biomarker analysis, including autoantibody levels FLU 25 mg/m2 x 3 days CY 1000 mg/m2 x 1 day Day -5 to Day -3 Discontinuation of all immunomodulatory agents

------

![Slide 18](g78097ex99_2s18g1.jpg)

Designed to evaluate the safety and tolerability of rese-cel in subjects with active, refractory disease Key inclusion and exclusion criteria in RESETTM clinical program ASyS, antisynthetase syndrome; CAR, chimeric antigen receptor; DM, dermatomyositis; HSCT, hematopoietic stem cell transplantation; IIM, idiopathic inflammatory myopathy; JIIM, juvenile idiopathic inflammatory myopathy; LN, lupus nephritis; MAA, myositis-associated antibody; SLEDAI-2k, SLE disease activity index 2000; SSc, systemic sclerosis. 1. ClinicalTrials.gov. Available at: www.clinicaltrials.gov/study/NCT06121297 (accessed October 2024). 2. ClinicalTrials.gov. Available at: www.clinicaltrials.gov/study/NCT06328777 (accessed October 2024). 3. ClinicalTrials.gov. Available at: www.clinicaltrials.gov/study/NCT06154252 (accessed October 2024). RESET-SLE™ Diagnosis of SLE (SLE or LN) Age ≥18 and ≤65 Positive ANA or anti-dsDNA at screening SLE (non-renal): active, moderate to severe SLE, SLEDAI-2K ≥8; pure class V LN eligible LN: active, biopsy-proven LN class III or IV (± class V) RESET-Myositis™ Diagnosis of IIM (ASyS, DM, or IMNM) Age ≥18 and ≤75 Presence of at least one myositis antibody JIIM: Age ≥6 and ≤17 with presence of at least one MSA or MAA Diagnosis of SSc limited or diffuse Age ≥18 and ≤75 Evidence of significant skin, pulmonary, renal, or cardiac involvement RESET-SSc™ Evidence of active disease despite prior or current treatment with standard of care Key inclusion criteria1–3 Key exclusion criteria1–3 B cell-depleting agent within prior 3-6 months; Previous CAR T therapy and/or HSCT Presence of kidney disease other than LN Current symptoms of severe, progressive, or uncontrolled pulmonary or cardiac disease Cancer-associated myositis Significant lung or cardiac impairment Severe lung or cardiac impairment Anticipate enrolling and completing dosing in multiple disease-specific cohorts in 2025; similarly designed RESET-MG™ Phase 1/2 trial rapidly enrolling

------

![Slide 19](g78097ex99_2s19g1.jpg)

Peak rese-cel expansion and transient peripheral B cell depletion occurred within ~2 weeks post infusion Rese-cel expansion & B cell kinetics across indications \*LN-1 had prolonged rese-cel detection due to TCR activation that corresponded to longer time to B cell repopulation. LN-4: follow up ongoing ASyS, antisynthetase syndrome; CAR, chimeric antigen receptor; DM, dermatomyositis; IMNM, immune-mediated necrotizing myopathy; LN, lupus nephritis; rese-cel, resecabtagene autoleucel; RESET, REstoring SElf-Tolerance; SLE, systemic lupus erythematosus, SSc, systemic sclerosis, TCR, T cell receptor. Cabaletta Bio: Data on file. RESET-Myositis RESET-SLE RESET-SSc Rese-cel Pharmacokinetics Rese-cel Pharmacokinetics\* Rese-cel Pharmacokinetics B Cell Kinetics B Cell Kinetics B Cell Kinetics Peripheral B cells began repopulating ~2 to 3 months after rese-cel in patients with sufficient follow-up\*

------

![Slide 20](g78097ex99_2s20g1.jpg)

Tissue resident depletion, consistent with the deep B cell depletion in circulation, observed via lymph node biopsy Lymph node B cell depletion in SSc-Skin-11 \*Lymph node biopsies were from the left inguinal area using USG at U. Mich. by Dr. Khanna. CAR, chimeric antigen receptor; rese-cel, resecabtagene autoleucel; mAb, monoclonal antibody; RESET, REstoring SElf-Tolerance; SSc, systemic sclerosis. 1. Cabaletta Bio: Data on File. 2. Tur C, et al. Ann Rheum Dis. 2025;84(1):106–114. B cell depletion observed to date is consistent with an academic study in autoimmune disease showing CD19-CAR T cell therapy achieves deeper depletion than mAbs2 Baseline Day 21 T cells (CD3) B cells (CD20) B cells (CD19)

------

![Slide 21](g78097ex99_2s21g1.jpg)

All patients had active, refractory disease and most had failed IVIg and B cell-targeting therapies Baseline Characteristics: First 8 Patients in RESET-Myositis\* \*As of May 6, 2025. ^Patient(s) who had clinical data presented in February 2025 scientific meetings. †Baseline disease activity = activity before preconditioning. ASyS, antisynthetase syndrome; AZA, azathioprine; CK, creatine kinase; DM, dermatomyositis; GC, glucocorticoid; HCQ, hydroxychloroquine; HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; IMNM, immune-mediated necrotizing myopathy; IVIg, intravenous immunoglobulin; MMF, mycophenolate mofetil; MMT-8, manual muscle testing 8; MTX, methotrexate; NXP, nuclear matrix protein; RESET, REstoring SElf-Tolerance; RTX, rituximab; SAE, small ubiquitin-like modifier activating enzyme; SRP, signal recognition particle; TAC, tacrolimus; TOC, tocilizumab; U/L, units per liter; y, years. Cabaletta Bio: Data on File. RESET-Myositis™ RESET-Myositis Cohort DM ASyS IMNM Patient DM-1^ DM-2 ASyS-1 ASyS-2 IMNM-1^ IMNM-2^ IMNM-3 IMNM-4 Age, sex 57 M 45 F 39 M 48 F 33 M 60 M 55 M 64 M Disease duration (y) ~4 ~2 ~4 ~15 ~2 ~4 ~1 ~6 Autoantibodies SAE NXP-2; Ro Jo-1; Ro-52 Jo-1; Ro-52 SRP HMGCR SRP; Ro-52 HMGCR Baseline disease activity† MMT-8 131 117 119 140 130 126 105 108 CK (U/L) 94 39 502 121 617 4725 1447 529 Therapies at Screening GC, MMF, HCQ IVIg, MMF, HCQ GC, IVIg, TAC GC, IVIg, MMF, TAC GC, MTX GC, IVIg MTX, AZA GC, IVIg, MMF Other prior therapies IVIg GC, RTX, TAC RTX, MMF, TOC, AZA RTX, MTX, MMF, AZA RTX, IVIg RTX, MTX, MMF GC AZA GC dose at Screening (mg/day) 20 NA 10 5 5 5 NA 10

------

![Slide 22](g78097ex99_2s22g1.jpg)

Fever (Grade 1 CRS) in 4 of 8 patients and no ICANS in any patients Incidence of relevant and related serious adverse events\* \*As of May 6, 2025; primary endpoint is incidence and severity of adverse events through Day 29. ^Patient(s) who had clinical data presented in February 2025 scientific meetings. †Graded per ASTCT Consensus Grading Criteria. DM-1, DM-2, ASyS-1, ASyS-2, and IMNM-3 received medication for seizure prophylaxis. Tocilizumab was administered for CRS for DM-2, ASyS-1, ASyS-2, and IMNM-3. ‡Coded in System Organ Class of Infections and Infestations and meets seriousness criteria. §As assessed per US Food and Drug Administration guidelines. ASTCT, American Society for Transplantation and Cellular Therapy; ASyS, antisynthetase syndrome; CRS, cytokine release syndrome; DM, dermatomyositis; ICANS, immune effector cell-associated neurotoxicity syndrome; IMNM, immune-mediated necrotizing myopathy; SAE, serious adverse event; RESET, REstoring SElf-Tolerance. Cabaletta Bio: Data on File. RESET-Myositis™ Cohort DM ASyS IMNM Patient DM-1^ DM-2 ASyS-1 ASyS-2 IMNM-1^ IMNM-2^ IMNM-3 IMNM-4 CRS† None Grade 1 Grade 1 Grade 1 None None Grade 1 None ICANS† None None None None None None None None Serious infections‡ None None None None None None None None Related SAEs (Grade)§ (excluding CRS and ICANS) None None None None None None None None

------

![Slide 23](g78097ex99_2s23g1.jpg)

Clinical responses have been observed off immunomodulators and glucocorticoids in all patients DM & ASyS: Efficacy data following rese-cel infusion\* \*As of May 6, 2025. †DM-1 Week 32 CK value not available; Week 28 CK value used for TIS calculation. ^Patient(s) who had clinical data presented in February 2025 scientific meetings. ASyS, antisynthetase syndrome; CK, creatine kinase; DM, dermatomyositis; HCQ, hydroxychloroquine; IVIg, intravenous immunoglobulin; MMF, mycophenolate mofetil; MMT-8, manual muscle testing 8; rese-cel, resecabtagene autoleucel; TAC, tacrolimus; TIS, total improvement score; U/L, units per liter. Cabaletta Bio: Data on File. TIS responses to rese-cel among all DM and ASyS patients show potential for achieving drug-free remission in patients with refractory myositis TIS Major Moderate Minimal None Discontinued all immunomodulators TIS DM ASyS Patient DM-1^ DM-2 ASyS-1 ASyS-2 Latest follow-up 32 weeks 8 weeks 12 weeks 8 weeks TIS Response Major Major Major Minimal to moderate GC-free ü ü ü ü IM-free ü ü ü ü DM-1 DM-2 ASyS-1 ASyS-2 MMF, HCQ IVIg, MMF, HCQ IVIg, TAC IVIg, MMF, TAC †

------

![Slide 24](g78097ex99_2s24g1.jpg)

Clinical responses have been observed off immunomodulators in 3 of 4 patients IMNM: Efficacy data following rese-cel infusion1\* \*As of May 6, 2025. ^Patient(s) who had clinical data presented in February 2025 scientific meetings. †Minimal to moderate improvement at all time points from Week 20, except for Week 48. ‡The subject experienced an unrelated life-threatening pulmonary embolism resulting in prolonged hospitalization and critical illness myopathy and was treated with intravenous immunoglobulin and prednisone after the Week 12 visit, confounding assessments of treatment response. Subject then began weekly IVIg after the Week 24 visit. ¶Tapering prednisone dose. †† IMNM-1 Day 29 CK measurement was unavailable; Day 22 measurement was used in its place and in calculation of the TIS score. § IMNM-2 Week 16 MMT-8 measurement was normalized to a total score of 150, calculated based on the collected value (96) and the maximum possible value (110). The normalized MMT-8 score was used to calculate the TIS for IMNM-2 at Week 16. AZA, azathioprine; CK, creatine kinase; GC, glucocorticoids; IM, immunomodulatory medication; IMNM, immune-mediated necrotizing myopathy; IVIg, intravenous immunoglobulin; MMF, mycophenolate mofetil; MMT-8, manual muscle testing 8; MTX, methotrexate; rese-cel, resecabtagene autoleucel; TIS, total improvement score; U/L, units per liter. 1. Cabaletta Bio: Data on File. 2. Schett, G. 'CAR-T Cell Therapy: "The Future is Now."' 5th Global Conference on Myositis. iMyoS. Pittsburgh, PA. Initial clinical responses in IMNM-1, IMNM-3, and IMNM-4 are consistent with published data1,2; slower and more modest TIS response in IMNM compared to other myositis subtypes TIS Major Moderate Minimal None Discontinued all immunomodulators †† § IMNM-2 has persistently elevated HMGCR Abs that likely arise from CD19-CD38+CD138+ long-lived plasma cells IMNM Patient IMNM-1^ IMNM-2^ IMNM-3 IMNM-4 Latest follow-up 56 weeks 28 weeks 16 weeks 4 weeks TIS Response Minimal to moderate† No change‡ Minimal to moderate Moderate GC-free ü -- ü --¶ IM-free ü -- ü ü IMNM-1 IMNM-2 IMNM-3 IMNM-4 MTX IVIg – has since restarted MTX, AZA IVIg, MMF

------

![Slide 25](g78097ex99_2s25g1.jpg)

All patients had active, refractory disease and had failed B cell-targeting therapies Baseline characteristics: First 8 patients in RESET-SLE\* \*As of June 2, 2025. ^Patient(s) who had clinical data presented in February 2025 scientific meetings. †Baseline disease activity = activity before preconditioning. ‡Inclusion criteria for LN cohort requires class III/IV LN (± class V). §All patients were antinuclear antibody positive at screening. \*\*SLE-4 initiated 20 mg/day of prednisone after screening and before leukapheresis, tapering off by Week 12. ADA, adalimumab; ANI, anifrolumab; AZA, azathioprine; BEL, belimumab; CYC, cyclophosphamide; dsDNA, double-stranded DNA; GC, glucocorticoid; HCQ, hydroxychloroquine; LEF, leflunomide; LN, lupus nephritis; MMF, mycophenolate mofetil; MSC, mesenchymal stem cell; MTX, methotrexate; N/A, not applicable; OBI, obinutuzumab; RESET, REstoring SElf-Tolerance; RTX, rituximab; SLE, systemic lupus erythematosus; SLEDAI-2K, SLE Disease Activity Index 2000; Sm, Smith; TAC, tacrolimus; TOC, tocilizumab; UPCR, urine protein-to-creatinine ratio; UST, ustekinumab; VOC, voclosporin, y, years. Cabaletta Bio: Data on File. Non-renal SLE LN Patient / Cohort SLE-1‡^ SLE-2^ SLE-3^ SLE-4^ LN-1^ LN-2^ LN-3 LN-4 Age, sex 26 M 36 F 44 F 37 F 24 F 35 F 26 F 18 M Disease duration (y) ~6 ~17 ~9 ~10 ~2 ~8 ~16 ~4 Autoantibodies§ dsDNA, Sm dsDNA dsDNA dsDNA, Sm dsDNA, Sm dsDNA, Sm Sm dsDNA LN class V N/A N/A N/A III IV + V III + V IV SLEDAI-2K† 26 10 8 8 22 14 16 16 UPCR (mg/mg)† 1.08† N/A N/A N/A 7.22 4.85 2.04 1.69 Therapies at screening HCQ, GC, MMF GC, AZA HCQ, MMF, BEL HCQ\*\* HCQ, GC, MMF, ANI, VOC MMF HCQ, MMF HCQ, GC, MMF,TAC, BEL Other prior therapies CYC, BEL, VOC, TAC HCQ, MTX, ANI, BEL, MSC, RTX, ADA GC, MTX GC, MTX, BEL BEL, LEF HCQ, GC, AZA, RTX GC, MTX, AZA, TOC, UST, RTX, OBI CYC, RTX, OBI GC dose at screening (mg/day) 10 7 N/A N/A\*\* 20 N/A N/A 5

------

![Slide 26](g78097ex99_2s26g1.jpg)

Fever (Grade 1 CRS) reported in 2 of 8 patients & ICANS reported in 1 of 8 patients Incidence of relevant and related serious adverse events\* \*As of June 2, 2025; Primary endpoint is incidence and severity of adverse events through Day 29. ^Patient(s) who had clinical data presented in February 2025 scientific meetings. †Graded per ASTCT Consensus Grading Criteria. All patients except SLE-1 and LN-1 received medication for seizure prophylaxis. Tocilizumab was administered for CRS in SLE-2. ‡Coded in System Organ Class of Infections and Infestations and meets seriousness criteria. §As assessed per US Food and Drug Administration guidelines. ¶Consistent with "Prolonged Cytopenias," which is a labeled warning and precaution for approved oncology CAR T products. \*\*LN-4: Week 4 safety data presented; efficacy follow up ongoing. ASTCT, American Society for Transplantation and Cellular Therapy; CAR, chimeric antigen receptor; CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; LN, lupus nephritis; SAE, serious adverse event; SLE, systemic lupus erythematosus. Cabaletta Bio: Data on File. Non-renal SLE LN Patient / Cohort SLE-1†^ SLE-2^ SLE-3^ SLE-4^ LN-1^ LN-2^ LN-3 LN-4\*\* CRS† None Grade 1 None None Grade 1 None None None ICANS† None None None None Grade 4 None None None Serious infections‡ None None None None None None None None Related SAEs (Grade)§ (Excluding CRS/ICANS) None None None None Fever (1) Neutropenic fever (1) Pancytopenia¶ (4) None None None

------

![Slide 27](g78097ex99_2s27g1.jpg)

As of the latest follow up, 3 of 4 SLE patients§ achieved DORIS Non-renal SLE: Efficacy data following rese-cel infusion\* \*As of June 2, 2025. ^Patient(s) who had clinical data presented in February 2025 scientific meetings. †Enrollment in the LN cohort requires class III/IV +/- V LN. SLE-1 had pure class V LN and extra-renal SLE disease activity that met inclusion criteria for the non-renal cohort. ‡SLEDAI-2K components present at latest follow up (SLEDAI-2K contribution score in parenthesis): SLE-1: hematuria (4), proteinuria (4), complement (2), increased DNA binding (2); SLE-2: increased DNA binding (2); SLE-3: increased DNA binding (2); SLE-4: increased DNA binding (2). §SLE-1 achieved DORIS at Week 48 and CRR at Week 44 and Week 48; on cyclosporine therapy since Week 41 for a non-SLE-related, non-rese-cel-related safety event (macrophage activation syndrome with onset at Week 40). CRR, complete renal response; DORIS, definition of remission in SLE; eGFR, estimated glomerular filtration rate; GC, glucocorticoid; IM, immunomodulatory; LN, lupus nephritis; N/A, not applicable; rese-cel, resecabtagene autoleucel; SLE, systemic lupus erythematosus; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000; UPCR, urine protein-creatinine ratio. DORIS = Clinical SLEDAI-2K=0 (irrespective of serology); Physician Global Assessment <0.5; antimalarials; low-dose glucocorticoids (prednisolone ≤5 mg/day); stable immunosuppressives including biologics. CRR = UPCR ≤0.5 mg/mg; ≥60 mL/min or no confirmed eGFR decrease of >20% from baseline; no receipt of rescue therapy. Cabaletta Bio: Data on File. Non-renal SLE Patient SLE-1†^ SLE-2^ SLE-3^ SLE-4^ Latest follow-up Week 52 Week 32 Week 28 Week 24 DORIS (at latest follow-up) ‒§ ü ü ü SLEDAI-2K score‡ (baseline to latest follow-up) 26→12 10→2 8→2 8→2 UPCR (mg/mg) (baseline to latest follow-up) 1.08→1.71 N/A N/A N/A eGFR (mL/min/1.73m2) (baseline to latest follow-up) 132.7→118.5 N/A N/A N/A CRR (at latest follow-up) ‒§ N/A N/A N/A GC-free ü ü ü ü IM-free ü§ ü ü ü

------

![Slide 28](g78097ex99_2s28g1.jpg)

As of the latest follow up 1st LN patient achieved CRR LN: Efficacy data following rese-cel infusion\* \*As of June 2, 2025. ^Patient(s) who had clinical data presented in February 2025 scientific meetings. ‡SLEDAI-2K components present at latest follow up (SLEDAI-2K contribution score in parenthesis): LN-2: proteinuria (4), increased DNA binding (2); LN-3: hematuria (4), proteinuria (4), pyuria (4). \*\*LN-2 Week 24 UPCR = 24hr UPCR. ††LN-4: efficacy follow up ongoing. CRR, complete renal response; DORIS, definition of remission in SLE; eGFR, estimated glomerular filtration rate; GC, glucocorticoid; IM, immunomodulatory; LN, lupus nephritis; N/A, not applicable; rese-cel, resecabtagene autoleucel; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000; UPCR, urine protein-creatinine ratio. DORIS = Clinical SLEDAI-2K=0 (irrespective of serology); Physician Global Assessment <0.5; antimalarials; low-dose glucocorticoids (prednisolone ≤5 mg/day); stable immunosuppressives including biologics. CRR = UPCR ≤0.5 mg/mg; ≥60 mL/min or no confirmed eGFR decrease of >20% from baseline; no receipt of rescue therapy. Cabaletta Bio: Data on File. LN†† Patient LN-1^ LN-2^ LN-3 Latest follow-up Week 44 Week 24 Week 12 DORIS (at latest follow-up) ü N/A N/A SLEDAI-2K score‡ (baseline to latest follow-up) 22→0 14→6 16→12 UPCR (mg/mg) (baseline to latest follow-up) 7.22→0.24 4.85→2.72\*\* 2.04→2.02 eGFR (mL/min/1.73m2) (baseline to latest follow-up) 72.3→130.9 127.2→125.8 133.2→128.8 CRR (at latest follow-up) ü ‒ ‒ GC-free ü ü ü IM-free ü ü ü

------

![Slide 29](g78097ex99_2s29g1.jpg)

Baseline characteristics & serious adverse events in first 2 SSc patients\* \*As of May 6, 2025; primary endpoint is incidence and severity of adverse events through Day 29. ^Patient(s) who had clinical data presented in February 2025 scientific meetings. \*\*Baseline disease activity = activity before preconditioning. †Per patient history and HRCT †† Graded per ASTCT Consensus Grading Criteria. Both patients received medication for seizure prophylaxis. ‡As assessed per US Food and Drug Administration guidelines. ASTCT, American Society for Transplantation and Cellular Therapy; BID, twice per day; BRX, brentuximab vedotin; CRS, cytokine release syndrome; DLCO, % predicted diffusing capacity for carbon monoxide; FVC, forced vital capacity; GC, glucocorticoid; HAQ-DI, Health Assessment Questionnaire Disability Index; HCQ, hydroxychloroquine; ICANS, immune effector cell-associated neurotoxicity syndrome; ICE, immune effector cell-associated encephalopathy; ILD, interstitial lung disease; MMF, mycophenolate mofetil; mRSS, modified Rodnan skin score; SAE, serious adverse event; PFT, pulmonary function test; RESET, REstoring SElf-Tolerance; RNA Pol III, ribonucleic acid polymerase III; SSc, systemic sclerosis; y, years. Cabaletta Bio: Data on File. Incidence of relevant and related serious adverse events\* CRS†† Grade 2 None ICANS†† None Grade 3 Serious infections None None Related SAEs‡ (Grade) (excluding CRS & ICANS) None Neutropenic fever (1) RESET-SSc™ Patient / Cohort SSc-Skin-1^ (Severe skin cohort) SSc-Skin-2 (Severe skin cohort) Age, sex 66 F 55 F Disease duration (y) ~2 ~0.5 Autoantibodies RNA Pol III Scl-70 Baseline\*\* mRSS 42 38 Baseline\*\* HAQ-DI 2.25 2.125 Baseline\*\* PFTs (% predicted) FVC: 91; DLCO: 70 FVC: 93; DLCO: 58 ILD presence† ü - Therapies at Screening MMF (1500 mg BID) MMF (1500 mg BID), GC Other prior therapies HCQ, BRX (Investigational) None Glucocorticoid dose at Screening (mg/day) 0 5

------

![Slide 30](g78097ex99_2s30g1.jpg)

Improvements in both SSc patients after discontinuing immunomodulatory drugs and steroids RESET-SSc™: Efficacy data following rese-cel infusion1 \*As of May 6, 2025. †RNA Pol III IgG level performed locally at U Mich. ‡ Pulmonary evaluations not available for SSc-Skin-2 at Week 4. CRISS, Composite Response Index in Systemic Sclerosis; DLCO, % predicted diffusing capacity for carbon monoxide; FVC, % predicted forced vital capacity; GC, glucocorticoid; HRCT, high-resolution computed tomography; ILD, interstitial lung disease; MMF, mycophenolate mofetil; mRSS, modified Rodnan Skin Score (measure of skin thickness in SSc across 17 body areas, with a maximum score of 512); RNA Pol III, ribonucleic acid polymerase III; rese-cel, resecabtagene autoleucel; SSc, systemic sclerosis. 1. Cabaletta Bio: Data on File. 2. Khanna D, et al. J Scleroderma Relat Disord. 2017;2(1):11–18;. SSc-Skin-1 met revised CRISS response criteria starting at Week 12, supporting potential for a drug-free clinical response\* Overall mRSS (N=2) mRSS by body area (SSc-Skin-1) Pulmonary Evaluations (SSc-Skin-1)‡ Baseline Week 24 Anti-RNA Pol III Titer†: > 150 Anti-RNA Pol III Titer†: 23 Baseline Week 12 Week 24 DLCO 70% 85% 81% FVC 91% 97% 105% ILD Mild stabilization on HRCT MMF Discontinued: MMF, GC

------

![Slide 31](g78097ex99_2s31g1.jpg)

Preliminary evidence of vascular recovery or stabilization in the majority of fingers Nailfold capillaroscopy for SSc-Skin-1 after rese-cel rese-cel, resecabtagene autoleucel; RESET, REstoring SElf-Tolerance; SSc, systemic sclerosis. Cabaletta Bio: Data on File. Baseline Week 24

------

![Slide 32](g78097ex99_2s32g1.jpg)

Rese-cel Product/Process Innovations & Indication Expansion

------

![Slide 33](g78097ex99_2s33g1.jpg)

Manufacturing strategy to BLA submission LVV – lentiviral vector Oxford is a commercial supplier for lentiviral vector utilized in approved CAR T products. Lonza has extensive experience manufacturing commercial cell and gene therapies. Innovative Manufacturing: Clinical Supply: Penn has reliably provided timely product for years Advanced Therapies (AT) (formerly WuXi) partnership provides additional rese-cel supply Expanded partnership for automated manufacturing with Cellares and completed Technology Adoption Program Evaluating whole blood process to eliminate apheresis Commercial Supply: Commercial supply strategy in hand, with process qualification and validation activities, required for BLA submission, planned: LVV process at Oxford1, and 2) Drug product process at Lonza2 Commercial-ready drug product tech transfer process expected to be completed with Lonza in 2H25 Opportunity for additional manufacturing partners

------

![Slide 34](g78097ex99_2s34g1.jpg)

Removing preconditioning, automating process & eliminating apheresis are potential near-term advances Lowering COGS, increasing scale & optimizing patient experience T cell collection Rese-cel manufacture and harvest Improve patient & provider experience Rese-cel administration Apheresis Cell selection & activation Cell expansion Cell harvest Preconditioning Infusion Product release Post-production testing & QA review Reduce COGS Increase scale & flexibility CURRENT FUTURE Replace apheresis with blood draw Automate the process (Cellares) Shorten the process Automate release (Cellares) Rapid sterility Rolling QA review Remove preconditioning Outpatient infusion ~6 to 8 weeks ~3 to 4 weeks

------

![Slide 35](g78097ex99_2s35g1.jpg)

Corporate Summary

------

![Slide 36](g78097ex99_2s36g1.jpg)

Track record of operational success evaluating & developing novel cell therapy candidates in autoimmunity Cabaletta Bio leadership LEADERSHIP TEAM Anup Marda Chief Financial Officer Nicolette Sherman Chief HR Officer Michael Gerard General Counsel Steven Nichtberger, M.D. President, CEO & Chairman Heather Harte-Hall Chief Compliance Officer Gwendolyn Binder, Ph.D. President, Science & Technology SCIENTIFIC ADVISORY BOARD Aimee Payne, M.D., Ph.D. Co-Founder and Co-Chair Michael C. Milone, M.D., Ph.D. Co-Founder and Co-Chair Carl June, M.D. Jay Siegel, M.D. Drew Weissman, M.D., Ph.D. Iain McInnes, Ph.D., FRCP, FRSE, FMedSci Georg Schett, M.D. David J. Chang, M.D., M.P.H., FACR Chief Medical Officer Samik Basu, M.D. Chief Scientific Officer Arun Das, M.D. Chief Business Officer From Fortune.©2024 Fortune Media IP Limited. All rights reserved. Used under license. Sarah Yuan Chief Technology Officer Gerwin Winter Head of International

------

![Slide 37](g78097ex99_2s37g1.jpg)

Planning to leverage recent myositis FDA alignment and execution across the portfolio of indications Anticipated Rese-cel Milestones with 2027 BLA Submission Planned 1H25 2H25 1H26 2H26 Align with FDA on registrational cohort designs Present complete Phase 1/2 data Initiate enrollment in registrational cohorts No preconditioning (RESET-PV) CMC commercial supply readiness & innovation Dose escalation data2 Initial dose data Commercial process implemented Lupus SSc Myositis MG Lupus SSc MG Myositis Myositis FDA alignment: Safety comparability EULAR interim data Myositis, Lupus & SSc Initial clinical data w/ Cellares process3 CONFIDENTIAL Subject to data and FDA alignment on proposed registrational cohort design.. Subject to review of initial dose cohort data. Pending final agreement with Cellares to advance technology. Additional indication(s): Lupus, SSc & MG1

------

![Slide 38](g78097ex99_2s38g1.jpg)

Appendix

------

![Slide 39](g78097ex99_2s39g1.jpg)

TIS is a composite tool measuring a patient's relative improvement from their baseline Myositis outcomes captured through validated composite endpoint Major Total Improvement Score 100 80 0 Minimal Moderate 60 40 20 Week 24 Baseline Week 12 None Extramuscular Activity 20 max achievable score Manual Muscle Testing (MMT8) 32.5 max achievable score Patient Global Activity 10 max achievable score Physician Global Activity 20 max achievable score Health Assessment Questionnaire (HAQ) 10 max achievable score Muscle Enzymes 7.5 max achievable score Total improvement score (TIS) components TIS developed via conjoint analysis based continuous model using absolute percentage change in 6 core set measures (CSM): MMT8, Extramuscular Activity, Physician Global Activity, Health Assessment Questionnaire, Patient Global Activity, and Muscle Enzymes TIS is the sum of improvement scores in the 6 CSMs, with ceiling of potential effect likely higher in DM and ASyS than in IMNM given minimal extramuscular involvement Illustrative patient-specific TIS ceiling for milder disease Illustrative patient-specific TIS ceiling for more severe disease ASyS – antisynthetase syndrome; CSM – core set measure; DM – dermatomyositis; IMNM – immune-mediated necrotizing myopathy; IVIg – intravenous immunoglobulin. Aggarwal R et al. NEJM. 2022;387(14):1264-1278.

------

![Slide 40](g78097ex99_2s40g1.jpg)

Corporate Presentation JUNE 2025